Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | DBH | P09172 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | BAD | Q92934 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6726501 | 1.00 | CES2 (0.54) | CES2CES1KDM4EDBHGAA | |
| SCHEMBL19130713 | 0.88 | HPGD (0.48) | CES2CES1KDM4EDBHGAA | |
| SCHEMBL10121174 | 0.87 | KDM4E (0.62) | CES2CES1KDM4EDBHGAA | |
| SCHEMBL4869727 | 0.84 | CES2 (0.52) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL2448326 | 0.84 | CES2 (0.52) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL29077329 | 0.84 | CES2 (0.52) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL526237 | 0.83 | CES2 (0.46) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL25214258 | 0.82 | CES2 (0.50) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL1938267 | 0.82 | CES2 (0.50) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL3852076 | 0.82 | CES2 (0.50) | CES2CES1CA1CA2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400504-A1 | THIOPHENE RING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences (CN) | 2024-07-17 | — | — | EP | disclosed |
| CN-114853586-B | Preparation method of phenanthrene ketone derivative | 扬州市职业大学(扬州开放大学) | 2024-03-15 | — | — | CN | disclosed |
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023125825-A1 | ANTICORONVIRAL COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| US-11667606-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667621-B2 | Antiestrogen compounds | STEVENS INSTITUTE OF TECHNOLOGY (US) | 2023-06-06 | — | — | US | disclosed |
| US-5977357-A | Phenyl alkyl ketone substituted by cyclic amine and a process for the preparation thereof | CIBA SPECIALTY CHEMICAL CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5795985-A | Phenyl alkyl ketone substituted by cyclic amine and a process for the preparation thereof | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| US-5145885-A | Morpholine compound, binders | CIBA-GEIGY CORPORATION (US) | 1992-09-08 | — | — | US | disclosed |
| EP-0273647-B1 | COUMARAN DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1992-03-11 | — | — | EP | disclosed |
| US-4992547-A | Aminoaryl ketone photoinitiators | CIBA-GEIGY CORPORATION (US) | 1991-02-12 | — | — | US | disclosed |
| US-4857516-A | Coumaran derivatives and their pharmaceutical use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0273647-A1 | Coumaran derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-07-06 | — | — | EP | disclosed |
| US-4454350-A | Process for the acylation of halo- or trihalomethylbenzenes | RHONE-POULENC SPECIALITIES CHIMIQUES (FR) | 1984-06-12 | — | — | US | disclosed |
| US-RE30634-E | INSECTICIDES | SHELL OIL COMPANY (US) | 1981-06-02 | — | — | US | disclosed |
| US-4079149-A | INSECTICIDES | SHELL OIL COMPANY (US) | 1978-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667606-B2 | Thyromimetics | TPO, TSHR, TTR | CES2 1424/4885CES1 194/4885KDM4E 3895/4885 |
| US-11667621-B2 | Antiestrogen compounds | ESR1, ESR2, ESRRG | CES2 2344/4885CES1 1306/4885KDM4E 434/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | CES2 3202/4885CES1 1593/4885KDM4E 2846/4885 |
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | CES2 4194/4885CES1 2321/4885KDM4E 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.